| 沙利度胺联合放疗治疗食管癌的临床观察 |
| |
| 引用本文： | 于静萍,孙志强,倪新初,王坚,李毅,胡莉钧,李栋庆,孙苏平.沙利度胺联合放疗治疗食管癌的临床观察[J].中华放射医学与防护杂志,2012,32(4):369-373. |
| |
| 作者姓名： | 于静萍 孙志强 倪新初 王坚 李毅 胡莉钧 李栋庆 孙苏平 |
| |
| 作者单位： | 南京医科大学附属常州第二人民医院放疗科,常州,213003 |
| |
| 基金项目： | 常州市卫生局重大科技项目(ZD201105) |
| |
| 摘 要： | 目的 前瞻性研究沙利度胺干预下食管癌患者放疗过程中血清血管内皮生长因子(VEGF)水平的动态变化及近期疗效和耐受性.方法 采集86例食管癌患者放疗前、中、后的血清,应用酶联免疫吸附法( ELISA)测定血清VEGF水平,根据患者放疗中VEGF水平的变化给予沙利度胺干预,将83例(另外3例因不耐受放疗而中断治疗)患者分成服药组32例(放疗中VEGF水平升高或不变的患者给予口服沙利度胺至放疗结束)和未服药组51例(VEGF水平降低的患者不服用沙利度胺放疗至结束),观察沙利度胺干预下食管癌放疗的疗效及服用药物的安全性.另设30例健康对照组.结果 86例食管癌患者放疗前血清VEGF表达水平较30例健康对照者升高,差异有统计学意义(t=5.07,P＜0.01),且与原发肿瘤大小(t=4.55,P＜0.01)、淋巴结转移(t=7.50,P ＜0.01)、组织病理类型(F=3.40,P＜0.01)及临床分期均有关(t=2.52,P＜0.01),而与病变部位、远处转移、X射线分型、患者性别、年龄均无关(P均＞0.05).服药组患者放疗后较放疗中血清VEGF的表达水平降低(t=2.37,P＜0.05),放疗有效率为71.88％；未服药组患者放疗中、后血清VEGF的表达水平差异无统计学意义(t=0.18,P＞0.05),服药组与未服药组的患者比较,头晕、倦怠反应的发生率分别为62.50％和15.69％(x2=19.28,P=0.000),嗜睡的发生率分别为18.75％和1.96％(x2=5.168,P=0.023),Ⅲ-Ⅳ度食管炎发生率分别为12.50％和11.76％(x2=0.061,P=0.806),Ⅲ-Ⅳ度白细胞下降发生率分别为6.25％和9.80％(x2=0.026,P=0.872),Ⅲ～Ⅳ度血小板下降发生率分别为3.13％和5.88％(x2=0.002,P=0.965),Ⅲ～Ⅳ度恶心呕吐发生率分别为9.38％和27.45％(x2=2.913,P=0.088),过敏反应的发生率均为0.结论 沙利度胺能够降低食管癌患者血清VEGF的表达水平,患者服用沙利度胺后耐受性较好.
|
| 关 键 词： | 食管癌 放射治疗 血管内皮生长因子 沙利度胺 |
| 收稿时间： | 2012/1/12 0:00:00 |
Clinical effect observation of VEGF expression interfered by Thalidomide combined with radiotherapy in esophageal cancer treatment |
| |
| YU Jing-ping,SUN Zhi-qiang,NI Xin-chu,WANG Jian,LI Yi,HU Li-jun,LI Dong-qing and SUN Su-ping.Clinical effect observation of VEGF expression interfered by Thalidomide combined with radiotherapy in esophageal cancer treatment[J].Chinese Journal of Radiological Medicine and Protection,2012,32(4):369-373. |
| |
| Authors: | YU Jing-ping SUN Zhi-qiang NI Xin-chu WANG Jian LI Yi HU Li-jun LI Dong-qing and SUN Su-ping |
| |
| Institution: | Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China |
| |
| Abstract: | |
| |
| Keywords: | Esophageal cancer Radiotherapy Vascular endothelial growth factor Thalidomide |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中华放射医学与防护杂志》浏览原始摘要信息 |
| 点击此处可从《中华放射医学与防护杂志》下载免费的PDF全文 |
|
